LISDEXAMFETAMINE DIMESYLATE tablet, chewable

Lisdexamfetamine dimesylate by

Drug Labeling and Warnings

Lisdexamfetamine dimesylate by is a Prescription medication manufactured, distributed, or labeled by Novadoz Pharmaceuticals LLC, MSN Pharmaceuticals Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • BOXED WARNING (What is this?)

    WARNING: ABUSE, MISUSE, AND ADDICTION


    Lisdexamfetamine dimesylate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including lisdexamfetamine dimesylate, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
    Before prescribing lisdexamfetamine dimesylate, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout lisdexamfetamine dimesylate treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9.2)].


  • 1 INDICATIONS AND USAGE


    Lisdexamfetamine dimesylate chewable tablets are indicated for the treatment of:




    Limitations of Use:


    • Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older [see Use in Specific Populations (8.4)].
    • Lisdexamfetamine dimesylate chewable tablets are not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of lisdexamfetamine dimesylate chewable tablets for the treatment of obesity have not been established [see Warnings and Precautions (5.2)].
  • 2 DOSAGE AND ADMINISTRATION

    2.1 Pretreatment Screening

    Prior to treating patients with lisdexamfetamine dimesylate chewable tablets, assess:

    • for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) [see Warnings and Precautions (5.2)].
    • the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome before initiating lisdexamfetamine dimesylate chewable tablets [see Warnings and Precautions (5.8)].

    2.2 General Administration Information


    Take lisdexamfetamine dimesylate chewable tablets orally in the morning with or without food; avoid afternoon doses because of the potential for insomnia. Lisdexamfetamine dimesylate chewable tablets may be administered in one of the following ways:
    Information for lisdexamfetamine dimesylate chewable tablets:


    • Lisdexamfetamine dimesylate chewable tablets must be chewed thoroughly before swallowing.
      VYVANSE capsules can be substituted with lisdexamfetamine dimesylate chewable tablets on a unit per unit/mg per mg basis (for example, 30 mg capsules for 30 mg chewable tablet) [see Clinical Pharmacology (12.3)].


    Do not take anything less than one chewable tablet per day. A single dose should not be divided.


    2.3 Dosage for Treatment of ADHD


    The recommended starting dosage in adults and pediatric patients 6 years and older is 30 mg once daily in the morning. Dosage may be adjusted in increments of 10 mg or 20 mg at approximately weekly intervals up to maximum recommended dosage of 70 mg once daily [see Clinical Studies (14.1)].

    2.4 Dosage for Treatment of Moderate to Severe BED in Adults


    The recommended starting dosage in adults is 30 mg once daily to be titrated in increments of 20 mg at approximately weekly intervals to achieve the recommended target dose of 50 mg to 70 mg once daily. The maximum recommended dosage is 70 mg once daily [see Clinical Studies (14.2)]. Discontinue lisdexamfetamine dimesylate chewable tablets if binge eating does not improve.

    2.5 Dosage in Patients with Renal Impairment


    In patients with severe renal impairment (GFR 15 to < 30 mL/min/1.73 m2), the maximum dosage should not exceed 50 mg once daily. In patients with end stage renal disease (ESRD, GFR < 15 mL/min/1.73 m2), the maximum recommended dosage is 30 mg once daily [see Use in Specific Populations (8.6)].

    2.6 Dosage Modifications due to Drug Interactions


    Agents that alter urinary pH can impact urinary excretion and alter blood levels of amphetamine. Acidifying agents (e.g., ascorbic acid) decrease blood levels, while alkalinizing agents (e.g., sodium bicarbonate) increase blood levels. Adjust lisdexamfetamine dimesylate chewable tablets dosage accordingly [see Drug Interactions (7.1)].

  • 3 DOSAGE FORMS AND STRENGTHS


    Lisdexamfetamine dimesylate chewable tablets:

    • Chewable tablets 10 mg: White or off-white to mottled round shaped tablet debossed with 'm169' on one side and plain on the other side
    • Chewable tablets 20 mg: White or off-white to mottled hexagonal shaped tablet debossed with 'm170' on one side and plain on the other side
    • Chewable tablets 30 mg: White or off-white to mottled arc triangular shaped tablet debossed with 'm171' on one side and plain on the other side
    • Chewable tablets 40 mg: White or off-white to mottled capsule shaped tablet debossed with 'm172' on one side and plain on the other side
    • Chewable tablets 50 mg: White or off-white to mottled arc square shaped tablet debossed with 'm173' on one side and plain on the other side
    • Chewable tablets 60 mg: White or off-white to mottled arc diamond shaped tablet debossed with 'm174' on one side and plain on the other side
  • 4 CONTRAINDICATIONS


    Lisdexamfetamine dimesylate is contraindicated in patients with:

    • Known hypersensitivity to amphetamine products or other ingredients of lisdexamfetamine dimesylate. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in postmarketing reports [see Adverse Reactions (6.2)].
    • Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions (5.7) and Drug Interactions (7.1)].
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Abuse, Misuse, and Addiction


    Lisdexamfetamine dimesylate has a high potential for abuse and misuse. The use of lisdexamfetamine dimesylate exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. lisdexamfetamine dimesylate can be diverted for non-medical use into illicit channels or distribution [see Drug Abuse and Dependence (9.2)]. Misuse and abuse of CNS stimulants, including lisdexamfetamine dimesylate, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
    Before prescribing lisdexamfetamine dimesylate, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store lisdexamfetamine dimesylate in a safe place, preferably locked, and instruct patients to not give lisdexamfetamine dimesylate to anyone else. Throughout lisdexamfetamine dimesylate treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.


    5.2 Risks to Patients with Serious Cardiac Disease


    Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD dosage. Avoid lisdexamfetamine dimesylate use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease

    5.3 Increased Blood Pressure and Heart Rate


    CNS stimulants cause an increase in blood pressure (mean increase about 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Some patients may have larger increases.
    Monitor all lisdexamfetamine dimesylate-treated patients for potential tachycardia and hypertension.

    5.4 Psychiatric Adverse Reactions


    Exacerbation of Pre-existing Psychosis
    CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.
    Induction of a Manic Episode in Patients with Bipolar Disorder
    CNS stimulants may induce a manic or mixed episode. Prior to initiating lisdexamfetamine dimesylate treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).
    New Psychotic or Manic Symptoms
    CNS stimulants, at the recommended dosage, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania.In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant treated patients compared to 0% of placebo-treated patients. If such symptoms occur, consider discontinuing lisdexamfetamine dimesylate.




    5.5 Long-Term Suppression of Growth in Pediatric Patients


    CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients.
    In a 4-week, placebo-controlled trial of lisdexamfetamine dimesylate in pediatric patients ages 6 to 12 years old with ADHD, there was a dose-related decrease in weight in the lisdexamfetamine dimesylate groups compared to weight gain in the placebo group. Additionally, in studies of another stimulant, there was slowing of the increase in height [see Adverse Reactions (6.1)].
    Closely monitor growth (weight and height) in lisdexamfetamine dimesylate-treated pediatric patients. Patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted. Lisdexamfetamine dimesylate is not approved for use in pediatric patients below 6 years of age [see Use in Specific Populations (8.4)].


    5.6 Peripheral Vasculopathy, including Raynaud’s Phenomenon


    CNS stimulants, including lisdexamfetamine dimesylate, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown.
    Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in postmarketing reports and at the therapeutic dosages of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after  dosage reduction or discontinuation of the CNS stimulant.
    Careful observation for digital changes is necessary during lisdexamfetamine dimesylate treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for lisdexamfetamine dimesylate-treated patients who develop signs or symptoms of peripheral vasculopathy.


    5.7 Serotonin Syndrome


    Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort [see Drug Interactions (7.1)]. The co-administration with cytochrome P450 2D6 (CYP2D6) inhibitors may also increase the risk with increased exposure to the active metabolite of lisdexamfetamine dimesylate (dextroamphetamine). In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6 [see Drug Interactions (7.1)].

    Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

    Concomitant use of lisdexamfetamine dimesylate with MAOI drugs is contraindicated [see Contraindications (4)].

    Discontinue treatment with lisdexamfetamine dimesylate and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. If concomitant use of lisdexamfetamine dimesylate with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate lisdexamfetamine dimesylate with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome.

    5.8 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome


    CNS stimulants, including amphetamine, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette’s syndrome has also been reported [see Adverse Reactions (6.2)].
    Before initiating lisdexamfetamine dimesylate, assess the family history and clinically evaluate patients for tics or Tourette’s syndrome. Regularly monitor lisdexamfetamine dimesylate-treated patients for the emergence or worsening of tics or Tourette’s syndrome, and discontinue treatment if clinically appropriate.


  • 6 ADVERSE REACTIONS

    The following adverse reactions are discussed in greater detail in other sections of the labeling:

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    Attention Deficit Hyperactivity Disorder

    The safety data in this section is based on data from the 4-week controlled parallel-group clinical studies of lisdexamfetamine dimesylate in pediatric and adult patients with ADHD [see Clinical Studies (14.1)].

    Adverse Reactions Associated with Discontinuation of Treatment in ADHD Clinical Trials        
    In the controlled trial in pediatric patients ages 6 to 12 years (Study 1), 8% (18/218) of lisdexamfetamine dimesylate-treated patients discontinued due to adverse reactions compared to 0% (0/72) of placebo-treated patients. The most frequently reported adverse reactions (1% or more and twice rate of placebo) were ECG voltage criteria for ventricular hypertrophy, tic, vomiting, psychomotor hyperactivity, insomnia, decreased appetite and rash [2 instances for each adverse reaction, i.e., 2/218 (1%)]. Less frequently reported adverse reactions (less than 1% or less than twice rate of placebo) included abdominal pain upper, dry mouth, weight decreased, dizziness, somnolence, logorrhea, chest pain, anger and hypertension.  
    In the controlled trial in pediatric patients ages 13 to 17 years (Study 4), 3% (7/233) of lisdexamfetamine dimesylate-treated patients discontinued due to adverse reactions compared to 1% (1/77) of placebo-treated patients. The most frequently reported adverse reactions (1% or more and twice rate of placebo) were decreased appetite (2/233; 1%) and insomnia (2/233; 1%). Less frequently reported adverse reactions (less than 1% or less than twice rate of placebo) included irritability, dermatillomania, mood swings, and dyspnea.   
    In the controlled adult trial (Study 7), 6% (21/358) of lisdexamfetamine dimesylate-treated patients discontinued due to adverse reactions compared to 2% (1/62) of placebo-treated patients. The most frequently reported adverse reactions (1% or more and twice rate of placebo) were insomnia (8/358; 2%), tachycardia (3/358; 1%), irritability (2/358; 1%), hypertension (4/358; 1%), headache (2/358; 1%), anxiety (2/358; 1%), and dyspnea (3/358; 1%). Less frequently reported adverse reactions (less than 1% or less than twice rate of placebo) included palpitations, diarrhea, nausea, decreased appetite, dizziness, agitation, depression, paranoia and restlessness.

    Adverse Reactions Occurring at an Incidence of ≥5% or More Among lisdexamfetamine dimesylate Treated Patients with ADHD in Clinical Trials

    The most common adverse reactions (incidence ≥5% and at a rate at least twice placebo) reported in pediatric patients ages 6 to 17 years, and/or adults were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting.

    Adverse Reactions Occurring at an Incidence of 2% or More Among lisdexamfetamine dimesylate Treated Patients with ADHD in Clinical Trials
    Adverse reactions reported in the controlled trials in pediatric patients ages, 6 to 12 years (Study 1), pediatric patients ages 13 to 17 years (Study 4), and adult patients (Study 7) treated with lisdexamfetamine dimesylate or placebo are presented in Tables 1, 2 and 3 below.

    Table 1 Adverse Reactions Reported by 2% or More of Pediatric Patients Ages 6 to 12 Years with ADHD Taking Lisdexamfetamine      Dimesylate and Greater than or Equal to Twice the Incidence in Patients Taking Placebo in a 4-Week Clinical Trial (Study 1)

      
         		 Lisdexamfetamine
     Dimesylate
     (n=218)
         		 Placebo
     (n=72)
     
     Decreased Appetite
         		 39%
         		 4%
     
     Insomnia
         		 22%
         		 3%
     
     Abdominal Pain Upper
         		 12%
         		 6%
     
     Irritability
         		 10%
         		 0%
     
     Vomiting
         		 9%
         		 4%
     
     Weight Decreased
         		 9%
         		 1%
     
     Nausea
         		 6%
         		 3%
     
     Dry Mouth
         		 5%
         		 0%
     
     Dizziness
         		 5%
         		 0%
     
     Affect lability
         		 3%
         		 0%
     
     Rash
         		 3%
         		 0%
     
     Pyrexia
         		 2%
         		 1%
     
     Somnolence
         		 2%
         		 1%
     
     Tic
         		 2%
         		 0%
     
     Anorexia
         		 2%
         		 0%
     

    Table 2 Adverse Reactions Reported by 2% or More of Pediatric Patients Ages 13 to 17 Years with ADHD Taking Lisdexamfetamine Dimesylate and Greater than or Equal to Twice the Incidence in Patients Taking Placebo in a 4-Week Clinical Trial (Study 4)

      
         		 Lisdexamfetamine
     Dimesylate
     (n=233)
         		 Placebo
     (n=77)
     
     Decreased Appetite
         		 34%
         		 3%
     
     Insomnia
         		 13%
         		 4%
     
     Weight Decreased
         		 9%
         		 0%
     
     Dry Mouth
         		 4%
         		 1%
     
     Palpitations
         		 2%
         		 1%
     
     Anorexia
         		 2%
         		 0%
     
     Tremor
         		 2%
         		 0%
     

    Table 3 Adverse Reactions Reported by 2% or More of Adult Patients with ADHD Taking Lisdexamfetamine Dimesylate and Greater than or Equal to Twice the Incidence in Patients Taking Placebo in a 4-Week Clinical Trial (Study 7)

      
         		 Lisdexamfetamine
     Dimesylate
     (n=358)
         		 Placebo
     (n=62)
     
     Decreased Appetite
         		 27%
         		 2%
     
     Insomnia
         		 27%
         		 8%
     
     Dry Mouth
         		 26%
         		 3%
     
     Diarrhea
         		 7%
         		 0%
     
     Nausea
         		 7%
         		 0%
     
     Anxiety
         		 6%
         		 0%
     
     Anorexia
         		 5%
         		 0%
     
     Feeling Jittery
         		 4%
         		 0%
     
     Agitation
         		 3%
         		 0%
     
     Increased Blood Pressure
         		 3%
         		 0%
     
     Hyperhidrosis
         		 3%
         		 0%
     
     Restlessness
         		 3%
         		 0%
     
     Decreased Weight
         		 3%
         		 0%
     
     Dyspnea
         		 2%
         		 0%
     
     Increased Heart Rate
         		 2%
         		 0%
     
     Tremor
         		 2%
         		 0%
     
     Palpitations
         		 2%
         		 0%
     

    In addition, in the adult population erectile dysfunction was observed in 2.6% of males on lisdexamfetamine dimesylate and 0% on placebo; decreased libido was observed in 1.4% of subjects on lisdexamfetamine dimesylate and 0% on placebo.

    Weight Loss and Slowing Growth Rate in Pediatric Patients with ADHD
    In a controlled trial of lisdexamfetamine dimesylate in pediatric patients ages 6 to 12 years (Study 1), mean weight loss from baseline after 4 weeks of therapy was -0.9, -1.9, and -2.5 pounds, respectively, for patients receiving 30 mg, 50 mg, and 70 mg of lisdexamfetamine dimesylate, compared to a 1 pound weight gain for patients receiving placebo. Higher doses were associated with greater weight loss with 4 weeks of treatment. Careful follow-up for weight in pediatric patients ages 6 to 12 years who received lisdexamfetamine dimesylate over 12 months suggests that consistently medicated pediatric patients (i.e., treatment for 7 days per week throughout the year) have a slowing in growth rate, measured by body weight as demonstrated by an age- and sex-normalized mean change from baseline in percentile, of -13.4 over 1 year (average percentiles at baseline and 12 months were 60.9 and 47.2, respectively). In a 4-week controlled trial of lisdexamfetamine dimesylate in pediatric patients ages 13 to 17 years, mean weight loss from baseline to endpoint was -2.7, -4.3, and -4.8 lbs., respectively, for patients receiving 30 mg, 50 mg, and 70 mg of lisdexamfetamine dimesylate, compared to a 2.0 pound weight gain for patients receiving placebo.
    Careful follow-up of weight and height in pediatric patients ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated pediatric patients over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated pediatric patients ages 7 to 13 years (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development. In a controlled trial of amphetamine (d- to l-enantiomer ratio of 3:1) in pediatric patients ages 13 to 17 years, mean weight change from baseline within the initial 4 weeks of therapy was -1.1 pounds and -2.8 pounds, respectively, for patients receiving 10 mg and 20 mg of amphetamine. Higher doses were associated with greater weight loss within the initial 4 weeks of treatment [see Warnings and Precautions (5.5)].

    Weight Loss in Adults with ADHD

    In the controlled adult trial (Study 7), mean weight loss after 4 weeks of therapy was 2.8 pounds, 3.1 pounds, and 4.3 pounds, for patients receiving final doses of 30 mg, 50 mg, and 70 mg of lisdexamfetamine dimesylate, respectively, compared to a mean weight gain of 0.5 pounds for patients receiving placebo.

    Binge Eating Disorder

    The safety data in this section is based on data from two 12-week parallel group, flexible-dose, placebo-controlled studies in adults with BED [see Clinical Studies 14.2]. Patients with cardiovascular risk factors other than obesity and smoking were excluded.

    Adverse Reactions Associated with Discontinuation of Treatment in BED Clinical Trials
    In controlled trials of patients ages 18 to 55 years, 5.1% (19/373) of lisdexamfetamine dimesylate-treated patients discontinued due to adverse reactions compared to 2.4% (9/372) of placebo-treated patients. No single adverse reaction led to discontinuation in 1% or more of lisdexamfetamine dimesylate-treated patients. Less commonly reported adverse reactions (less than 1% or less than twice rate of placebo) included increased heart rate, headache, abdominal pain upper, dyspnea, rash, insomnia, irritability, feeling jittery and anxiety.
    Adverse Reactions Occurring at an Incidence of 5% or More and At Least Twice Placebo Among lisdexamfetamine dimesylate Treated Patients with BED in Clinical Trials
    The most common adverse reactions (incidence ≥5% and at a rate at least twice placebo) reported in adults were dry mouth, insomnia, decreased appetite, increased heart rate, constipation, feeling jittery, and anxiety.

       Adverse Reactions Occurring at an Incidence of 2% or More and At Least Twice Placebo Among lisdexamfetamine dimesylate Treated Patients with BED in Clinical Trials
    Adverse reactions reported in the pooled controlled trials in adult patients (Study 11 and 12) treated with lisdexamfetamine dimesylate or placebo are presented in Table 4 below.
    Table 4 Adverse Reactions Reported by 2% or More of Adult Patients with BED Taking Lisdexamfetamine Dimesylate and Greater than or Equal to Twice the Incidence in Patients Taking Placebo in 12-Week Clinical Trials (Study 11 and 12)

      
         		 Lisdexamfetamine Dimesylate
     (N=373)
         		 Placebo
     (N=372)
     
     Dry Mouth
         		 36%
         		 7%
     
     Insomnia1
         		 20%
         		 8%
     
     Decreased Appetite
         		 8%
         		 2%
     
     Increased Heart Rate2
         		 7%
         		 1%
     
     Feeling Jittery
         		 6%
         		 1%
     
     Constipation
         		 6%
         		 1%
     
     Anxiety
         		 5%
         		 1%
     
     Diarrhea
         		 4%
         		 2%
     
     Decreased Weight
         		 4%
         		 0%
     
     Hyperhidrosis
         		 4%
         		 0%
     
     Vomiting
         		 2%
         		 1%
     
     Gastroenteritis
         		 2%
         		 1%
     
     Paresthesia
         		 2%
         		 1%
     
     Pruritus
         		 2%
         		 1%
     
     Upper Abdominal Pain
         		 2%
         		 0%
     
     Energy Increased
         		 2%
         		 0%
     
     Urinary Tract Infection
         		 2%
         		 0%
     
     Nightmare
         		 2%
         		 0%
     
     Restlessness
         		 2%
         		 0%
     
     Oropharyngeal Pain
         		 2%
         		 0%
     

    1Includes all preferred terms containing the word “insomnia.”
    2Includes the preferred terms “heart rate increased” and “tachycardia.”

    6.2 Postmarketing Experience


    The following adverse reactions have been identified during post-approval use of lisdexamfetamine dimesylate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events are as follows: cardiomyopathy, mydriasis, diplopia, difficulties with visual accommodation, blurred vision, eosinophilic hepatitis, anaphylactic reaction, hypersensitivity, dyskinesia, dysgeusia, motor and verbal tics, bruxism, depression, dermatillomania, alopecia, aggression, Stevens-Johnson Syndrome, chest pain, angioedema, urticaria, seizures, libido changes, frequent or prolonged erections, constipation, rhabdomyolysis, and intestinal ischemia.

  • 7 DRUG INTERACTIONS

    7.1 Drugs Having Clinically Important Interactions with Amphetamines

    Table 5 Drugs having clinically important interactions with amphetamines.

     MAO Inhibitors (MAOI)
     
     Clinical Impact
         		 MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results.
     
     Intervention
         		 Do not administer lisdexamfetamine dimesylate during or within 14 days following the administration of MAOI [see Contraindications (4)].
     
     Serotonergic Drugs
     
     Clinical Impact
         		 The concomitant use of lisdexamfetamine dimesylate and serotonergic drugs increases the risk of serotonin syndrome.
     
     Intervention
         		 Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during lisdexamfetamine dimesylate initiation or dosage increase. If serotonin syndrome occurs, discontinue lisdexamfetamine dimesylate and the concomitant serotonergic drug(s) [see Warnings and Precautions (5.7)].
     
     CYP2D6 Inhibitors
     
     Clinical Impact
         		 The concomitant use of lisdexamfetamine dimesylate and CYP2D6 inhibitors may increase the exposure of dextroamphetamine, the active metabolite of lisdexamfetamine dimesylate compared to the use of the drug alone and increase the risk of serotonin syndrome.
     
     Intervention
         		 Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during lisdexamfetamine dimesylate initiation and after a dosage increase. If serotonin syndrome occurs, discontinue lisdexamfetamine dimesylate and the CYP2D6 inhibitor [see Warnings and Precautions (5.7) and Overdosage (10)].
     
     Alkalinizing Agents
     
     Clinical Impact
         		 Urinary alkalinizing agents can increase blood levels and potentiate the action of amphetamine.
     
     Intervention
         		 Co-administration of lisdexamfetamine dimesylate and urinary alkalinizing agents should be avoided.
     
     Acidifying Agents
     
     Clinical Impact
         		 Urinary acidifying agents can lower blood levels and efficacy of amphetamines.
     
     Intervention
         		 Increase dose based on clinical response.
     
     Tricyclic Antidepressants
     
     Clinical Impact
         		 May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.
     
     Intervention
         		 Monitor frequently and adjust or use alternative therapy based on clinical response.
     

    7.2 Drugs Having No Clinically Important Interactions with Lisdexamfetamine Dimesylate


    From a pharmacokinetic perspective, no dose adjustment of lisdexamfetamine dimesylate is necessary when lisdexamfetamine dimesylate is co-administered with guanfacine, venlafaxine, or omeprazole. In addition, no dose adjustment of guanfacine or venlafaxine is needed when lisdexamfetamine dimesylate is co-administered [see Clinical Pharmacology (12.3)].

    From a pharmacokinetic perspective, no dose adjustment for drugs that are substrates of CYP1A2 (e.g., theophylline, duloxetine, melatonin), CYP2D6 (e.g., atomoxetine, desipramine, venlafaxine), CYP2C19 (e.g., omeprazole, lansoprazole, clobazam), and CYP3A4 (e.g., midazolam, pimozide, simvastatin) is necessary when lisdexamfetamine dimesylate is co-administered [see Clinical Pharmacology (12.3)].

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy


    Pregnancy Exposure Registry
    There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and researchprograms/pregnancyregistry/adhdmedications/.

    Risk Summary
    The limited available data from published literature and postmarketing reports on use of lisdexamfetamine dimesylate in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. Adverse pregnancy outcomes, including premature delivery and low birth weight, have been seen in infants born to mothers dependent on amphetamines [see Clinical Considerations]. In animal reproduction studies, lisdexamfetamine dimesylate (a prodrug of d-amphetamine) had no effects on embryo-fetal morphological development or survival when administered orally to pregnant rats and rabbits throughout the period of organogenesis. Pre- and postnatal studies were not conducted with lisdexamfetamine dimesylate. However, amphetamine (d- to l- ratio of 3:1) administration to pregnant rats during gestation and lactation caused a decrease in pup survival and a decrease in pup body weight that correlated with a delay in developmental landmarks at clinically relevant doses of amphetamine. In addition, adverse effects on reproductive performance were observed in pups whose mothers were treated with amphetamine. Long-term neurochemical and behavioral effects have also been reported in animal developmental studies using clinically relevant doses of amphetamine [see Data].

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    Clinical Considerations
    Fetal/Neonatal Adverse Reactions
    Amphetamines, such as lisdexamfetamine dimesylate, cause vasoconstriction and thereby may decrease placental perfusion. In addition, amphetamines can stimulate uterine contractions increasing the risk of premature delivery. Infants born to amphetamine-dependent mothers have an increased risk of premature delivery and low birth weight.

    Monitor infants born to mothers taking amphetamines for symptoms of withdrawal such as feeding difficulties, irritability, agitation, and excessive drowsiness.

    Data
    Animal Data
    Lisdexamfetamine dimesylate had no apparent effects on embryo-fetal morphological development or survival when administered orally to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 40 and 120 mg/kg/day, respectively. These doses are approximately 5.5 and 33 times, respectively, the maximum recommended human dose (MRHD) of 70 mg/day given to adults, on a mg/m2 body surface area basis.

    A study was conducted with amphetamine (d- to l- enantiomer ratio of 3:1) in which pregnant rats received daily oral doses of 2, 6, and 10 mg/kg from gestation day 6 to lactation day 20. All doses caused hyperactivity and decreased weight gain in the dams. A decrease in pup survival was seen at all doses. A decrease in pup body weight was seen at 6 and 10 mg/kg which correlated with delays in developmental landmarks, such as preputial separation and vaginal opening. Increased pup locomotor activity was seen at 10 mg/kg on day 22 postpartum but not at 5 weeks postweaning. When pups were tested for reproductive performance at maturation, gestational weight gain, number of implantations, and number of delivered pups were decreased in the group whose mothers had been given 10 mg/kg.

    A number of studies from the literature in rodents indicate that prenatal or early postnatal exposure to amphetamine (d- or d, l-) at doses similar to those used clinically can result in long-term neurochemical and behavioral alterations. Reported behavioral effects include learning and memory deficits, altered locomotor activity, and changes in sexual function.


    8.2 Lactation


    Risk Summary
    Lisdexamfetamine is a pro-drug of dextroamphetamine. Based on limited case reports in published literature, amphetamine (d-or d, 1-) is present in human milk, at relative infant doses of 2% to 13.8% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.9 and 7.5. There are no reports of adverse effects on the breastfed infant. Long-term neurodevelopmental effects on infants from amphetamine exposure are unknown. It is possible that large dosages of dextroamphetamine might interfere with milk production, especially in women whose lactation is not well established. Because of the potential for serious adverse reactions in nursing infants, including serious cardiovascular reactions, blood pressure and heart rate increase, suppression of growth, and peripheral vasculopathy, advise patients that breastfeeding is not recommended during treatment with lisdexamfetamine dimesylate.


    8.4 Pediatric Use


    ADHD
    Safety and effectiveness of lisdexamfetamine dimesylate have been established in pediatric patients with ADHD ages 6 to 17 years [see Dosage and Administration (2.3), Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.1)].

    Safety and effectiveness of lisdexamfetamine dimesylate have not been established in pediatric patients below the age of 6 years.

    Safety and efficacy of lisdexamfetamine dimesylate were evaluated in a double-blind, randomized, parallel-group, placebo-controlled, fixed-dose study in pediatric patients ages 4 to 5 years with ADHD, followed by a 1-year open-label extension study. In these studies, patients experienced elevated rates of adverse reactions, including weight loss, decreased BMI, decreased appetite, insomnia, infections (upper respiratory and nasopharyngitis), irritability, and affect lability.

    With the same lisdexamfetamine dimesylate dose, mean steady state exposure of dextroamphetamine was approximately 44% higher in pediatric patients ages 4 to 5 years compared to the pediatric patients ages 6 to 11 years.

    BED
    Safety and effectiveness of lisdexamfetamine dimesylate have not been established in pediatric patients with BED less than 18 years of age.

    Growth Suppression
    Growth should be monitored during treatment with stimulants, including lisdexamfetamine dimesylate, and pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted [see Warnings and Precautions (5.5) and Adverse Reactions (6.1)].

    Juvenile Animal Data
    Studies conducted in juvenile rats and dogs at clinically relevant doses showed growth suppression that partially or fully reversed in dogs and female rats but not in male rats after a four-week drug-free recovery period.

    A study was conducted in which juvenile rats received oral doses of 4, 10, or 40 mg/kg/day of lisdexamfetamine dimesylate from day 7 to day 63 of age. These doses are approximately 0.3, 0.7, and 3 times the maximum recommended human daily dose of 70 mg on a mg/m2 basis for a child. Dose-related decreases in food consumption, bodyweight gain, and crown-rump length were seen; after a four-week drug-free recovery period, bodyweights and crown-rump lengths had significantly recovered in females but were still substantially reduced in males. Time to vaginal opening was delayed in females at the highest dose, but there were no drug effects on fertility when the animals were mated beginning on day 85 of age.
    In a study in which juvenile dogs received lisdexamfetamine dimesylate for 6 months beginning at 10 weeks of age, decreased bodyweight gain was seen at all doses tested (2, 5, and 12 mg/kg/day, which are approximately 0.5, 1, and 3 times the maximum recommended human daily dose on a mg/m2 basis for a child). This effect partially or fully reversed during a four-week drug-free recovery period.

    8.5 Geriatric Use


    Clinical studies of lisdexamfetamine dimesylate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience and pharmacokinetic data [see Clinical Pharmacology (12.3)] have not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

    8.6 Renal Impairment


    Due to reduced clearance in patients with severe renal impairment (GFR 15 to < 30 mL/min/1.73 m2), the maximum dose should not exceed 50 mg/day. The maximum recommended dose in ESRD (GFR < 15 mL/min/1.73 m2) patients is 30 mg/day [see Clinical Pharmacology (12.3)].

    Lisdexamfetamine and d-amphetamine are not dialyzable.

  • 9 DRUG ABUSE AND DEPENDENCE

    9.1 Controlled Substance


    Lisdexamfetamine dimesylate chewable tablet contains lisdexamfetamine, a prodrug of amphetamine, a Schedule II controlled substance.

    9.2 Abuse


    Lisdexamfetamine dimesylate has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction [see Warnings and Precautions (5.1)]. Lisdexamfetamine dimesylate can be diverted for non-medical use into illicit channels or distribution.
    Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.
    Misuse and abuse of lisdexamfetamine, a prodrug of amphetamine, may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils;  hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including lisdexamfetamine dimesylate, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
    Studies of Lisdexamfetamine Dimesylate in Drug Abusers
    A randomized, double-blind, placebo-control, cross-over, abuse liability study in 38 patients with a history of drug abuse was conducted with single-doses of 50, 100, or 150 mg of lisdexamfetamine dimesylate, 40 mg of immediate-release d-amphetamine sulphate (a controlled II substance), and 200 mg of diethylpropion hydrochloride (a controlled IV substance). Lisdexamfetamine dimesylate 100 mg produced significantly less “Drug Liking Effects” as measured by the Drug Rating Questionnaire-Subject score, compared to d-amphetamine 40 mg; and 150 mg of lisdexamfetamine dimesylate demonstrated similar “Drug-Liking Effects” compared to 40 mg of d-amphetamine and 200 mg of diethylpropion.
    Intravenous administration of 50 mg lisdexamfetamine dimesylate to individuals with a history of drug abuse produced positive subjective responses on scales measuring “Drug Liking”, “Euphoria”, “Amphetamine Effects”, and “Benzedrine Effects” that were greater than placebo but less than those produced by an equivalent dose (20 mg) of intravenous d-amphetamine.


    9.3 Dependence


    Physical Dependence
    Lisdexamfetamine dimesylate may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including lisdexamfetamine dimesylate include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.
    Tolerance
    Lisdexamfetamine dimesylate may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).


  • 10 OVERDOSAGE

    Clinical Effects of Overdose
    Overdose of CNS stimulants is characterized by the following sympathomimetic effects:

    • Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop.
    • CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur.
    • Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis may develop.
       

    Overdose Management
    Consider the possibility of multiple drug ingestion. The pharmacokinetic profile of lisdexamfetamine dimesylate should be considered when treating patients with overdose. Lisdexamfetamine and damphetamine are not dialyzable. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.


  • 11 DESCRIPTION


    Lisdexamfetamine dimesylate chewable tablet, a CNS stimulant, is for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl]-hexanamide dimethanesulfonate. The molecular formula is C15H25N3O(CH4O3S)2, which corresponds to a molecular weight of 455.60. The chemical structure is:



    lisdex-dimesy-chew-tabs-structure



    Lisdexamfetamine dimesylate is a white to off-white powder that is soluble in water (792 mg/mL).

    Information for lisdexamfetamine dimesylate chewable tablets:
    Lisdexamfetamine dimesylate chewable tablets contain 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg of lisdexamfetamine dimesylate (equivalent to 5.8 mg, 11.6 mg, 17.3 mg, 23.1 mg, 28.9 mg, and 34.7 mg of lisdexamfetamine).

    Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose and gaur gum, sucralose, N-C strawberry flavor art.


  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action


    Lisdexamfetamine is a prodrug of dextroamphetamine. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD and BED is not known.

    12.2 Pharmacodynamics


    Amphetamines block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. The parent drug, lisdexamfetamine, does not bind to the sites responsible for the reuptake of norepinephrine and dopamine in vitro.

    12.3 Pharmacokinetics


    Pharmacokinetic studies after oral administration of lisdexamfetamine dimesylate have been conducted in healthy adult (capsule and chewable tablet formulations) and pediatric (6 to 12 years) patients with ADHD (capsule formulation). After single dose administration of lisdexamfetamine dimesylate, pharmacokinetics of dextroamphetamine was found to be linear between 30 mg and 70 mg in a pediatric study (6 to 12 years), and between 50 mg and 250 mg in an adult study. Dextroamphetamine pharmacokinetic parameters following administration of lisdexamfetamine dimesylate in adults exhibited low inter-subject (<25%) and intra-subject (<8%) variability. There is no accumulation of lisdexamfetamine and dextroamphetamine at steady state in healthy adults.

    Absorption
    Capsule formulation
    Following single-dose oral administration of VYVANSE capsule (30 mg, 50 mg, or 70 mg) in patients ages 6 to 12 years with ADHD under fasted conditions, Tmax of lisdexamfetamine and dextroamphetamine was reached at approximately 1 hour and 3.5 hours post dose, respectively. Weight/Dose normalized AUC and Cmax values were the same in pediatric patients ages 6 to 12 years as the adults following single doses of 30 mg to 70 mg VYVANSE capsule.

    Effect of food on capsule formulation


    Neither food (a high fat meal or yogurt) nor orange juice affects the observed AUC and Cmax of dextroamphetamine in healthy adults after single-dose oral administration of 70 mg of VYVANSE capsules. Food prolongs Tmax by approximately 1 hour (from 3.8 hours at fasted state to 4.7 hours after a high fat meal or to 4.2 hours with yogurt). After an 8-hour fast, the AUC for dextroamphetamine following oral administration of lisdexamfetamine dimesylate in solution and as intact capsules were equivalent.
    Chewable Tablet formulation
    After a single dose administration of 60 mg lisdexamfetamine dimesylate chewable tablet in healthy subjects under fasted conditions, Tmax of lisdexamfetamine and dextroamphetamine was reached at approximately 1 hour and 4.4 hours post dose, respectively. Compared to 60 mg VYVANSE capsule, exposure (Cmax and AUC) to lisdexamfetamine was about 15% lower. The exposure (Cmax and AUCinf) of dextroamphetamine is similar between lisdexamfetamine dimesylate chewable tablet and VYVANSE capsule.

    Effect of food on tablet formulation
    Administration of 60 mg lisdexamfetamine dimesylate chewable tablet with food (a high-fat meal) decreases the exposure (Cmax and AUCinf) of dextroamphetamine by about 5% to 7%, and prolongs mean Tmax by approximately 1 hour (from 3.9 hours at fasted state to 4.9 hours).

    Elimination
    Plasma concentrations of unconverted lisdexamfetamine are low and transient, generally becoming non-quantifiable by 8 hours after administration. The plasma elimination half-life of lisdexamfetamine typically averaged less than one hour in volunteers ages 6 years and older. The plasma elimination half-life of dextroamphetamine was approximately 8.6 to 9.5 hours in pediatric patients 6 to 12 years and 10 to 11.3 hours in healthy adults.

    Metabolism
    Lisdexamfetamine is converted to dextroamphetamine and l-lysine primarily in blood due to the hydrolytic activity of red blood cells after oral administration of lisdexamfetamine dimesylate. In vitro data demonstrated that red blood cells have a high capacity for metabolism of lisdexamfetamine; substantial hydrolysis occurred even at low hematocrit levels (33% of normal). Lisdexamfetamine is not metabolized by cytochrome P450 enzymes.

    Excretion
    Following oral administration of a 70 mg dose of radiolabeled lisdexamfetamine dimesylate to 6 healthy subjects, approximately 96% of the oral dose radioactivity was recovered in the urine and only 0.3% recovered in the feces over a period of 120 hours. Of the radioactivity recovered in the urine, 42% of the dose was related to amphetamine, 25% to hippuric acid, and 2% to intact lisdexamfetamine.

    Specific Populations
    Exposures of dextroamphetamine in specific populations are summarized in Figure 1.
    Figure 1: Specific Populations*:
     

    lisdex-dimesy-chew-tabs-fig-01




    *Figure 1 shows the geometric mean ratios and the 90% confidence limits for Cmax and AUC of d-amphetamine.
    Comparison for gender uses males as the reference. Comparison for age uses 55 to 64 years as the reference.

    Drug Interaction Studies
    Effects of other drugs on the exposures of dextroamphetamine are summarized in Figure 2.

    Figure 2: Effect of Other Drugs on Lisdexamfetamine Dimesylate:

    lisdex-dimesy-chew-tabs-fig-02




    The effects of lisdexamfetamine dimesylate on the exposures of other drugs are summarized in Figure 3.

    Figure 3: Effect of Lisdexamfetamine Dimesylate on Other Drugs:

    lisdex-dimesy-chew-tabs-fig-03


  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility


    Carcinogenesis
    Carcinogenicity studies of lisdexamfetamine dimesylate have not been performed. No evidence of carcinogenicity was found in studies in which d-, l-amphetamine (enantiomer ratio of 1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats.

    Mutagenesis
    Lisdexamfetamine dimesylate was not clastogenic in the mouse bone marrow micronucleus test in vivo and was negative when tested in the E. coli and S.typhimurium components of the Ames test and in the L5178Y/TK+/- mouse lymphoma assay in vitro.

    Impairment of Fertility
    Amphetamine (d- to l-enantiomer ratio of 3:1) did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day.


    13.2 Animal Toxicology and/or Pharmacology


    Acute administration of high doses of amphetamine (d- or d, 1-) has been shown to produce long-lasting neurotoxic effects, including irreversible nerve fiber damage, in rodents. The significance of these findings to humans is unknown.

  • 14 CLINICAL STUDIES

    14.1 Attention Deficit Hyperactivity Disorder (ADHD)

    Pediatric Patients Ages 6 to 12 Years with ADHD
    A double-blind, randomized, placebo-controlled, parallel-group study (Study 1) was conducted in pediatric patients ages 6 to 12 years (N=290) who met DSM-IV criteria for ADHD (either the combined type or the hyperactive-impulsive type). Patients were randomized to receive final doses of 30 mg, 50 mg, or 70 mg of lisdexamfetamine dimesylate or placebo once daily in the morning for a total of four weeks of treatment. All patients receiving lisdexamfetamine dimesylate were initiated on 30 mg for the first week of treatment. Patients assigned to the 50 mg and 70 mg dose groups were titrated by 20 mg per week until they achieved their assigned dose. The primary efficacy outcome was change in Total Score from baseline to endpoint in investigator ratings on the ADHD Rating Scale (ADHD-RS), an 18-item questionnaire with a score range of 0-54 points that measures the core symptoms of ADHD which includes both hyperactive/impulsive and inattentive subscales. Endpoint was defined as the last post-randomization treatment week (i.e., Weeks 1 through 4) for which a valid score was obtained. All lisdexamfetamine dimesylate dose groups were superior to placebo in the primary efficacy outcome. Mean effects at all doses were similar; however, the highest dose (70 mg/day) was numerically superior to both lower doses (Study 1 in Table 6). The effects were maintained throughout the day based on parent ratings (Conners’ Parent Rating Scale) in the morning (approximately 10 am), afternoon (approximately 2 pm), and early evening (approximately 6 pm).

    A double-blind, placebo-controlled, randomized, crossover design, analog classroom study (Study 2) was conducted in pediatric patients ages 6 to 12 years (N=52) who met DSM-IV criteria for ADHD (either the combined type or the hyperactive-impulsive type). Following a 3-week open-label dose optimization with Adderall XR®, patients were randomly assigned to continue their optimized dose of Adderall XR (10 mg, 20 mg, or 30 mg), lisdexamfetamine dimesylate (30 mg, 50 mg, or 70 mg), or placebo once daily in the morning for 1 week each treatment. Efficacy assessments were conducted at 1, 2, 3, 4.5, 6, 8, 10, and 12 hours post-dose using the Swanson, Kotkin, Agler, M.Flynn, and Pelham Deportment scores (SKAMP-DS), a 4-item subscale of the SKAMP with scores ranging from 0 to 24 points that measures deportment problems leading to classroom disruptions. A significant difference in patient behavior, based upon the average of investigator ratings on the SKAMP-DS across the 8 assessments were observed between patients when they received lisdexamfetamine dimesylate compared to patients when they received placebo (Study 2 in Table 6). The drug effect reached statistical significance from hours 2 to 12 post-dose, but was not significant at 1 hour.

    A second double-blind, placebo-controlled, randomized, crossover design, analog classroom study (Study 3) was conducted in pediatric patients ages 6 to 12 years (N=129) who met DSM-IV criteria for ADHD (either the combined type or the hyperactive-impulsive type). Following a 4-week open-label dose optimization with lisdexamfetamine dimesylate (30 mg, 50 mg, 70 mg), patients were randomly assigned to continue their optimized dose of lisdexamfetamine dimesylate or placebo once daily in the morning for 1 week each treatment. A significant difference in patient behavior, based upon the average of investigator ratings on the SKAMP-Deportment scores across all 7 assessments conducted at 1.5, 2.5, 5.0, 7.5, 10.0, 12.0, and 13.0 hours post-dose, were observed between patients when they received lisdexamfetamine dimesylate compared to patients when they received placebo (Study 3 in Table 6, Figure 4).

    Pediatric Patients Ages 13 to 17 Years with ADHD
    A double-blind, randomized, placebo-controlled, parallel-group study (Study 4) was conducted in pediatric patients ages 13 to 17 years (N=314) who met DSM-IV criteria for ADHD. In this study, patients were randomized in a 1:1:1:1 ratio to a daily morning dose of lisdexamfetamine dimesylate (30 mg/day, 50 mg/day or 70 mg/day) or placebo for a total of four weeks of treatment. All patients receiving lisdexamfetamine dimesylate were initiated on 30 mg for the first week of treatment. Patients assigned to the 50 mg and 70 mg dose groups were titrated by 20 mg per week until they achieved their assigned dose. The primary efficacy outcome was change in Total Score from baseline to endpoint in investigator ratings on the ADHD Rating Scale (ADHD-RS). Endpoint was defined as the last post-randomization treatment week (i.e., Weeks 1 through 4) for which a valid score was obtained. All lisdexamfetamine dimesylate dose groups were superior to placebo in the primary efficacy outcome (Study 4 in Table 6).
    Pediatric Patients Ages 6 to 17 Years: Short-Term Treatment in ADHD
    A double-blind, randomized, placebo- and active-controlled parallel-group, dose-optimization study (Study 5) was conducted in pediatric patients ages 6 to 17 years (n=336) who met DSM-IV criteria for ADHD. In this eight-week study, patients were randomized to a daily morning dose of lisdexamfetamine dimesylate (30, 50 or 70 mg/day), an active control, or placebo (1:1:1). The study consisted of a Screening and Washout Period (up to 42 days), a 7-week Double-blind Evaluation Period (consisting of a 4-week Dose-Optimization Period followed by a 3-week Dose-Maintenance Period), and a 1-week Washout and Follow-up Period. During the Dose Optimization Period, subjects were titrated until an optimal dose, based on tolerability and investigator’s judgment, was reached. Lisdexamfetamine dimesylate showed significantly greater efficacy than placebo. The placebo-adjusted mean reduction from baseline in the ADHD-RS-IV total score was 18.6. Subjects on lisdexamfetamine dimesylate also showed greater improvement on the Clinical Global Impression-Improvement (CGI-I) rating scale compared to subjects on placebo (Study 5 in Table 6).
    Pediatric Patients Ages 6 to 17 Years: Maintenance Treatment in ADHD
    Maintenance of Efficacy Study (Study 6) - A double-blind, placebo-controlled, randomized withdrawal study was conducted in pediatric patients ages 6 to 17 years (N=276) who met the diagnosis of ADHD (DSM-IV criteria). A total of 276 patients were enrolled into the study, 236 patients participated in Study 5 and 40 subjects directly enrolled. Subjects were treated with open-label lisdexamfetamine dimesylate for at least 26 weeks prior to being assessed for entry into the randomized withdrawal period. Eligible patients had to demonstrate treatment response as defined by CGI-S <3 and Total Score on the ADHD-RS ≤22. Patients that maintained treatment response for 2 weeks at the end of the open label treatment period were eligible to be randomized to ongoing treatment with the same dose of lisdexamfetamine dimesylate (N=78) or switched to placebo (N=79) during the double-blind phase. Patients were observed for relapse (treatment failure) during the 6 week double blind phase. A significantly lower proportion of treatment failures occurred among lisdexamfetamine dimesylate subjects (15.8%) compared to placebo (67.5%) at endpoint of the randomized withdrawal period. The endpoint measurement was defined as the last post-randomization treatment week at which a valid ADHD-RS Total Score and CGI-S were observed. Treatment failure was defined as a ≥50% increase (worsening) in the ADHD-RS Total Score and a ≥2-point increase in the CGI-S score compared to scores at entry into the double-blind randomized withdrawal phase. Subjects who withdrew from the randomized withdrawal period and who did not provide efficacy data at their last on-treatment visit were classified as treatment failures (Study 6, Figure 5).

    Adults: Short-Term Treatment in ADHD
    A double-blind, randomized, placebo-controlled, parallel-group study (Study 7) was conducted in adults ages 18 to 55 (N=420) who met DSM-IV criteria for ADHD. In this study, patients were randomized to receive final doses of 30 mg, 50 mg, or 70 mg of lisdexamfetamine dimesylate or placebo for a total of four weeks of treatment. All patients receiving lisdexamfetamine dimesylate were initiated on 30 mg for the first week of treatment. Patients assigned to the 50 mg and 70 mg dose groups were titrated by 20 mg per week until they achieved their assigned dose. The primary efficacy outcome was change in Total Score from baseline to endpoint in investigator ratings on the ADHD Rating Scale (ADHD-RS). Endpoint was defined as the last post-randomization treatment week (i.e., Weeks 1 through 4) for which a valid score was obtained. All lisdexamfetamine dimesylate dose groups were superior to placebo in the primary efficacy outcome (Study 7 in Table 6).
    The second study was a multi-center, randomized, double-blind, placebo-controlled, cross-over, modified analog classroom study (Study 8) of lisdexamfetamine dimesylate to simulate a workplace environment in 142 adults ages 18 to 55 who met DSM-IV-TR criteria for ADHD. There was a 4-week open-label, dose optimization phase with lisdexamfetamine dimesylate (30 mg/day, 50 mg/day, or 70 mg/day in the morning). Patients were then randomized to one of two treatment sequences: 1) lisdexamfetamine dimesylate (optimized dose) followed by placebo, each for one week, or 2) placebo followed by lisdexamfetamine dimesylate, each for one week. Efficacy assessments occurred at the end of each week, using the Permanent Product Measure of Performance (PERMP), a skill-adjusted math test that measures attention in ADHD. PERMP total score results from the sum of the number of math problems attempted plus the number of math problems answered correctly. Lisdexamfetamine dimesylate treatment, compared to placebo, resulted in a statistically significant improvement in attention across all post-dose time points, as measured by average PERMP total scores over the course of one assessment day, as well as at each time point measured. The PERMP assessments were administered at pre-dose (-0.5 hours) and at 2, 4, 8, 10, 12, and 14 hours post-dose (Study 8 in Table 6, Figure 6).

    Adults: Maintenance Treatment in ADHD 
    A double-blind, placebo-controlled, randomized withdrawal design study (Study 9) was conducted in adults ages 18 to 55 (N=123) who had a documented diagnosis of ADHD or met DSM-IV criteria for ADHD. At study entry, patients must have had documentation of treatment with lisdexamfetamine dimesylate for a minimum of 6 months and had to demonstrate treatment response as defined by Clinical Global Impression Severity (CGI-S) ≤3 and Total Score on the ADHD-RS <22. ADHD-RS Total Score is a measure of core symptoms of ADHD. The CGI-S score assesses the clinician’s impression of the patient’s current illness state and ranges from 1 (not at all ill) to 7 (extremely ill). Patients that maintained treatment response at Week 3 of the open label treatment phase (N=116) were eligible to be randomized to ongoing treatment with the same dose of lisdexamfetamine dimesylate (N=56) or switched to placebo (N=60) during the double-blind phase. Patients were observed for relapse (treatment failure) during the 6-week double-blind phase. The efficacy endpoint was the proportion of patients with treatment failure during the double-blind phase. Treatment failure was defined as a ≥50% increase (worsening) in the ADHD-RS Total Score and ≥2-point increase in the CGI-S score compared to scores at entry into the double-blind phase. Maintenance of efficacy for patients treated with lisdexamfetamine dimesylate was demonstrated by the significantly lower proportion of patients with treatment failure (9%) compared to patients receiving placebo (75%) at endpoint during the double-blind phase (Study 9, Figure 7).
    Table 6: Summary of Primary Efficacy Results from Short-term Studies of Lisdexamfetamine Dimesylate in Pediatric Patients (Ages 6 to 17) and Adults with ADHD

     Study
     Number
     (Age
     range)
         		 Primary
     Endpoint
      
         		 Treatment Group
      
         		 Mean Baseline Score (SD)
      
         		 LS Mean Change
     from Baseline (SE)
      
         		 Placebo-subtracted
     Differencea (95% CI)
      
     
     Study 1
     (6 -12 years)
      
         		 ADHD-RS-IV
      
         		 Lisdexamfetamine dimesylate
    (30 mg/day) *
    Lisdexamfetamine dimesylate
    (50 mg/day) *
    Lisdexamfetamine dimesylate
    (70 mg/day) *
      
     Placebo     		 43.2 (6.7)
      
     43.3 (6.7)
      
     45.1(6.8)
      
      
     42.4 (7.1)
      
         		 -21.8 (1.6)
      
     -23.4 (1.6)
      
     -26.7 (1.5)
      
      
     -6.2 (1.6)
      
         		 -15.6 (-19.9, -11.2)
      
     -17.2 (-21.5, -12.9)
      
     -20.5 (-24.8, -16.2)
      
      
     --
      
     
     Study 2
     (6 -12 years)
      
         		 Average SKAMP-DS
      
         		 Lisdexamfetamine dimesylate
    (30, 50 or 70 mg/day) *
      
      
    Placebo
      
         		 --b
      
      
      
     --b
      
         		 0.8 (0.1) d
      
      
      
     1.7 (0.1) d
      
         		 -0.9 (-1.1, -0.7)
      
      
      
     --
     
     Study 3
     (6 -12 years)
      
         		 Average SKAMP-DS
      
         		 Lisdexamfetamine dimesylate
    (30, 50 or 70 mg/day) *
      
      
    Placebo
      
         		 0.9 (1.0) c
      
      
      
     0.7 (0.9) c
      
         		 0.7 (0.1) d
      
      
      
     1.4 (0.1) d
      
         		 -0.7 (-0.9, -0.6)
      
      
      
     --
     
     Study 4
     (13 -17 years)
      
         		 ADHD-RS-IV
      
         		 Lisdexamfetamine dimesylate
    (30 mg/day) *
    Lisdexamfetamine dimesylate
    (50 mg/day) *
    Lisdexamfetamine dimesylate
    (70 mg/day) *
    Placebo  
         		 38.3 (6.7)
      
     37.3 (6.3)
      
     37.0 (7.3)
      
     38.5 (7.1)
      
         		 -18.3 (1.2)
      
     -21.1 (1.3)
      
     -20.7 (1.3)
      
     -12.8 (1.2)
      
         		 -5.5 (-9.0, -2.0)
      
     -8.3 (-11.8, -4.8)
      
     -7.9 (-11.4, -4.5)
      
     --
      
     
     Study 5
     (6 -17 years)
      
         		 ADHD-RS-IV
      
         		 Lisdexamfetamine dimesylate
    (30, 50 or 70 mg/day) *
      
      
    Placebo
      
         		 40.7 (7.3)
      
      
      
     41.0 (7.1)
      
         		 -24.3 (1.2)
      
      
      
     -5.7 (1.1)
      
         		 -18.6 (-21.5, -15.7)
      
      
      
     --
     
     Study 7
     (18 -55 years)
      
         		 ADHD-RS-IV
      
         		 Lisdexamfetamine dimesylate
    (30 mg/day) *
    Lisdexamfetamine dimesylate
    (50 mg/day) *
    Lisdexamfetamine dimesylate
    (70 mg/day) *
      
     Placebo   
         		 40.5 (6.2)
      
     40.8 (7.3)
      
     41.0 (6.0)
      
      
     39.4 (6.4)
      
         		 -16.2 (1.1)
      
     -17.4 (1.0)
      
     -18.6 (1.0)
      
      
     -8.2 (1.4)
      
         		 -8.0 (-11.5, -4.6)
      
     -9.2 (-12.6, -5.7)
      
     -10.4 (-13.9, -6.9)
      
      
     --
     
     Study 8 (18 -55 years)
      
         		 Average PERMP
      
         		 Lisdexamfetamine dimesylate
    (30, 50 or 70 mg/day) *
      
    Placebo
         		 260.1 (86.2) c
      
      
     261.4 (75.0) c
      
         		 312.9 (8.6) d
      
      
     289.5 (8.6) d
      
         		 23.4 (15.6, 31.2)
      
      
     --
     

    SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval.
    a Difference (drug minus placebo) in least-squares mean change from baseline.
    b Pre-dose SKAMP-DS was not collected.
    c Pre-dose SKAMP-DS (Study 3) or PERMP (Study 8) total score, averaged over both periods.
    d LS Mean for SKAMP-DS (Study 2 and 3) or PERMP (Study 8) is post-dose average score over all sessions of the treatment day, rather than

      change from baseline.
    * Doses statistically significantly superior to placebo.

    Figure 4 LS Mean SKAMP Deportment Subscale Score by Treatment and Time-point for Pediatric Patients Ages 6 to 12 with ADHD after 1 Week of Double Blind Treatment (Study 3)

    lisdex-dimesy-chew-tabs-fig-04  

    Higher score on the SKAMP-Deportment scale indicates more severe symptoms

    Figure 5 Kaplan-Meier Estimated Proportion of Patients with Treatment Failure for Pediatric Patients Ages 6 to 17 (Study 6)

    lisdex-dimesy-chew-tabs-fig-05  

    Figure 6 LS Mean (SE) PERMP Total Score by Treatment and Time-point for Adults Ages 18 to 55 with ADHD after 1 Week of Double Blind Treatment (Study 8)

    lisdex-dimesy-chew-tabs-fig-06  

    Higher score on the PERMP scale indicates less severe symptoms.

    Figure 7 Kaplan-Meier Estimated Proportion of Subjects with Relapse in Adults with ADHD (Study 9)

    lisdex-dimesy-chew-tabs-fig-07

        

    14.2 Binge Eating Disorder (BED)


    A phase 2 study evaluated the efficacy of lisdexamfetamine dimesylate 30, 50 and 70 mg/day compared to placebo in reducing the number of binge days/week in adults with at least moderate to severe BED. This randomized, double-blind, parallel-group, placebo-controlled, forced-dose titration study (Study 10) consisted of an 11-week double-blind treatment period (3 weeks of forced-dose titration followed by 8 weeks of dose maintenance). Lisdexamfetamine dimesylate 30 mg/day was not statistically different from placebo on the primary endpoint. The 50 and 70 mg/day doses were statistically superior to placebo on the primary endpoint.

    The efficacy of lisdexamfetamine dimesylate in the treatment of BED was demonstrated in two 12-week randomized, double-blind, multi-center, parallel-group, placebo-controlled, dose-optimization studies (Study 11 and Study 12) in adults aged 18-55 years (Study 11: N=374, Study 12: N=350) with moderate to severe BED. A diagnosis of BED was confirmed using DSM-IV criteria for BED. Severity of BED was determined based on having at least 3 binge days per week for 2 weeks prior to the baseline visit and on having a Clinical Global Impression Severity (CGI-S) score of ≥4 at the baseline visit. For both studies, a binge day was defined as a day with at least 1 binge episode, as determined from the subject’s daily binge diary.

    Both 12-week studies consisted of a 4-week dose-optimization period and an 8-week dose-maintenance period. During dose-optimization, subjects assigned to lisdexamfetamine dimesylate began treatment at the titration dose of 30 mg/day and, after 1 week of treatment, were subsequently titrated to 50 mg/day. Additional increases to 70 mg/day were made as tolerated and clinically indicated. Following the dose-optimization period, subjects continued on their optimized dose for the duration of the dose-maintenance period.

    The primary efficacy outcome for the two studies was defined as the change from baseline at Week 12 in the number of binge days per week. Baseline is defined as the weekly average of the number of binge days per week for the 14 days prior to the baseline visit. Subjects from both studies on lisdexamfetamine dimesylate had a statistically significantly greater reduction from baseline in mean number of binge days per week at Week 12. In addition, subjects on lisdexamfetamine dimesylate showed greater improvement as compared to placebo across key secondary outcomes with higher proportion of subjects rated improved on the CGI-I rating scale, higher proportion of subjects with 4-week binge cessation, and greater reduction in the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) total score.

    Table 7: Summary of Primary Efficacy Results in BED

     Study Number
      
         		 Treatment Group
      
         		  
     Primary Efficacy Measure: Binge Days per Week at Week 12
     
     Mean Baseline Score (SD)
      
         		 LS Mean Change from Baseline (SE)
      
         		 Placebo-subtracted Differencea (95% CI)
      
     
     Study 11
      
         		 Lisdexamfetamine dimesylate (50 or 70 mg/day) *
      
     Placebo
      
         		 4.79 (1.27)
      
      
      
     4.60 (1.21)
      
         		 -3.87 (0.12)
      
      
      
     -2.51 (0.13)
      
         		 -1.35 (-1.70, -1.01)
      
      
      
     --
     
     Study 12
         		 Lisdexamfetamine dimesylate (50 or 70 mg/day) *
      
     Placebo
      
         		 4.66 (1.27)
      
      
      
     4.82 (1.42)
      
         		 -3.92 (0.14)
      
      
      
     -2.26 (0.14)
      
         		 -1.66 (-2.04, -1.28)
      
      
      
     --
     

    SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval.
    a Difference (drug minus placebo) in least-squares mean change from baseline.
    * Doses statistically significantly superior to placebo.

    A double-blind, placebo controlled, randomized withdrawal design study (Study 13) was conducted to evaluate maintenance of efficacy based on time to relapse between lisdexamfetamine dimesylate and placebo in adults aged 18 to 55 (N=267) with moderate to severe BED. In this longer-term study patients who had responded to lisdexamfetamine dimesylate in the preceding 12-week open-label treatment phase were randomized to continuation of lisdexamfetamine dimesylate or placebo for up to 26 weeks of observation for relapse. Response in the open-label phase was defined as 1 or fewer binge days each week for four consecutive weeks prior to the last visit at the end of the 12-week open-label phase and a CGI-S score of 2 or less at the same visit. Relapse during the double-blind phase was defined as having 2 or more binge days each week for two consecutive weeks (14 days) prior to any visit and having an increase in CGI-S score of 2 or more points compared to the randomized-withdrawal baseline. Maintenance of efficacy for patients who had an initial response during the open-label period and then continued on lisdexamfetamine dimesylate during the 26-week double-blind randomized-withdrawal phase was demonstrated with lisdexamfetamine dimesylate being superior over placebo as measured by time to relapse.

    Figure 8 Kaplan-Meier Estimated Proportions of Subjects with Relapse in Adults with BED (Study 13)

    lisdex-dimesy-chew-tabs-fig-08  

    Examination of population subgroups based on age (there were no patients over 65), gender, and race did not reveal any clear evidence of differential responsiveness in the treatment of BED.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied


    Lisdexamfetamine dimesylate chewable tablets:


    • Lisdexamfetamine dimesylate chewable tablets 10 mg: White or off-white to mottled round shaped tablet debossed with 'm169' on one side and plain on the other side, bottles of 100, NDC: 72205-132-91
    • Lisdexamfetamine dimesylate chewable tablets 20 mg: White or off-white to mottled hexagonal shaped tablet debossed with 'm170' on one side and plain on the other side, bottles of 100, NDC: 72205-133-91
    • Lisdexamfetamine dimesylate chewable tablets 30 mg: White or off-white to mottled arc triangular shaped tablet debossed with 'm171' on one side and plain on the other side, bottles of 100, NDC: 72205-134-91
    • Lisdexamfetamine dimesylate chewable tablets 40 mg: White or off-white to mottled capsule shaped tablet debossed with 'm172' on one side and plain on the other side, bottles of 100, NDC: 72205-135-91
    • Lisdexamfetamine dimesylate chewable tablets 50 mg: White or off-white to mottled arc square shaped tablet debossed with 'm173' on one side and plain on the other side, bottles of 100, NDC: 72205-136-91
    • Lisdexamfetamine dimesylate chewable tablets 60 mg: White or off-white to mottled arc diamond shaped tablet debossed with 'm174' on one side and plain on the other side, bottles of 100, NDC: 72205-137-91

    16.2 Storage and Handling


    Dispense in a tight, light-resistant container as defined in the USP.

    Store at room temperature, 20ºC to 25ºC (68ºF to 77ºF). Excursions permitted between 15ºC and 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature].
     


  • 17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-approved patient labeling (Medication Guide).
    Abuse, Misuse, and Addiction
    Educate patients and their families about the risks of abuse, misuse, and addiction of lisdexamfetamine dimesylate, which can lead to overdose and death, and proper disposal of any unused drug [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9.2), Overdosage (10)]. Advise patients to store lisdexamfetamine dimesylate in a safe place, preferably locked, and instruct patients to not give lisdexamfetamine dimesylate to anyone else.
    Risks to Patients with Serious Cardiac Disease
    Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with lisdexamfetamine dimesylate use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease [see Warnings and Precautions (5.2)].
    Increased Blood Pressure and Heart Rate
    Instruct patients that lisdexamfetamine dimesylate can cause elevations of their blood pressure and pulse rate and they should be monitored for such effects.
    Psychiatric Adverse Reactions
    Advise patients that lisdexamfetamine dimesylate at recommended doses may cause psychotic or manic symptoms even in patients without prior history of psychotic symptoms or mania [see Warnings and Precautions (5.4)].
    Long-Term Suppression of Growth in Pediatric Patients
    Advise patients that lisdexamfetamine dimesylate may cause slowing of growth including weight loss [see Warnings and Precautions (5.5)].
    Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud’s phenomenon]
    Instruct patients beginning treatment with lisdexamfetamine dimesylate about the risk of peripheral vasculopathy, including Raynaud’s phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change from pale, to blue, to red. Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes. Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking lisdexamfetamine dimesylate. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients [see Warnings and Precautions (5.6)].
    Serotonin Syndrome
    Caution patients about the risk of serotonin syndrome with concomitant use of lisdexamfetamine dimesylate and other serotonergic drugs including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John’s Wort, and with drugs that impair metabolism of serotonin (in particular MAOIs, both those intended to treat psychiatric disorders and also others such as linezolid [see Contraindications (4),Warnings and Precautions (5.7) and Drug Interactions (7.1)]. Advise patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome.
    Concomitant Medications
    Advise patients to notify their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs because there is a potential for interactions [see Drug Interactions (7.1)].
    Motor and Verbal Tics, and Worsening of Tourette’s Syndrome
    Advise patients that motor and verbal tics and worsening of Tourette’s Syndrome may occur during treatment with lisdexamfetamine dimesylate. Instruct patients to notify their healthcare provider if emergence of new tics or worsening of tics or Tourette’s syndrome occurs [see Warnings and Precautions (5.8)].
    Pregnancy Registry
    Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lisdexamfetamine dimesylate during pregnancy [see Use in Specific Populations (8.1)].
    Pregnancy
    Advise patients of the potential fetal effects from the use of lisdexamfetamine dimesylate during pregnancy. Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with lisdexamfetamine dimesylate [see Use in Specific Populations (8.1)].
    Lactation
    Advise women not to breastfeed if they are taking lisdexamfetamine dimesylate [see Use in Specific Populations (8.2)].
    Administration Instructions

    Dispense with Medication Guide available at: www.NovadozPharma.com/Products


    For more-information call 1-855-668-2369
    The brands listed are trademarks of their respective owners and are not trademarks of Novadoz Pharmaceuticals LLC. The makers of these brands are not affiliated with and do not endorse Novadoz Pharmaceuticals LLC or its products.
    Manufactured by:
    MSN Pharmaceuticals Inc
    Piscataway, NJ 08854
    Distributed by:
    Novadoz Pharmaceuticals LLC
    Piscataway, NJ 08854-3714                                                                                                 
    Issued: 11/2023     


  • MEDICATION GUIDE


    Dispense with Medication Guide available at: www.NovadozPharma.com/Products                








    MEDICATION GUIDE
     Lisdexamfetamine dimesylate (lis dex′′ am fet′ a meen di·mes·y·late
    Chewable Tablets, CII

    What is the most important information I should know about lisdexamfetamine dimesylate chewable tablets?
    Lisdexamfetamine dimesylate chewable tablets may cause serious side effects, including: 
    • Abuse, misuse, and addiction. lisdexamfetamine dimesylate chewable tablets have a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of lisdexamfetamine dimesylate chewable tablets, other amphetamine containing medicines, and methylphenidate containing medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of lisdexamfetamine dimesylate chewable tablets or when it is used in ways that are not approved, such as snorting or injection.
    • Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment with lisdexamfetamine dimesylate chewable tablets and will monitor you or your child during treatment.
    • Lisdexamfetamine dimesylate chewable tablets may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider.
    • Do not give lisdexamfetamine dimesylate chewable tablets to anyone else. See “What is lisdexamfetamine dimesylate chewable tablets?” for more information.
    • Keep lisdexamfetamine dimesylate chewable tablets in a safe place and properly dispose of any unused medicine. See "How should I store lisdexamfetamine dimesylate chewable tablets?" for more information. 
    • Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
    • Risks for people with serious heart disease. Sudden death has happened in people who have heart defects or other serious heart disease.
      Your healthcare provider should check you or your child carefully for heart problems before starting treatment with lisdexamfetamine dimesylate chewable tablets. Tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects.
      Call your healthcare provider right away or go to the nearest hospital emergency room right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with lisdexamfetamine dimesylate chewable tablets. 
    • Increased blood pressure and heart rate.
      Your healthcare provider should check you or your child’s blood pressure and heart rate regularly during treatment with lisdexamfetamine dimesylate chewable tablets.
    • Mental (psychiatric) problems, including:
    • new or worse behavior and thought problems
    • new or worse bipolar illness
    • new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manic symptoms
    Tell your healthcare provider about any mental problems you or your child have or about a family history of suicide, bipolar illness, or depression.
    Call your healthcare provider right away if you or your child have any new or worsening mental symptoms or problems during treatment with lisdexamfetamine dimesylate chewable tablets, especially hearing voices, seeing or believing things that are not real, or new manic symptoms.
    What are lisdexamfetamine dimesylate chewable tablets?
    Lisdexamfetamine dimesylate chewable tablets are a central nervous system (CNS) stimulant prescription medicine used for the treatment of:
    • Attention Deficit Hyperactivity Disorder (ADHD) in adults and children 6 years of age and older. Lisdexamfetamine dimesylate chewable tablets may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.             
    • Moderate to severe binge eating disorder (BED) in adults. Lisdexamfetamine dimesylate chewable tablets may help reduce the number of binge eating days in people with BED.
    Lisdexamfetamine dimesylate chewable tablets are not for use in children under 6 years of age with ADHD.
    Lisdexamfetamine dimesylate chewable tablets are not for weight loss. It is not known if lisdexamfetamine dimesylate chewable tablets are safe and effective for the treatment of obesity.  
    It is not known if lisdexamfetamine dimesylate chewable tablets are safe and effective for use in children with BED.
    Lisdexamfetamine dimesylate chewable tablets are a federally controlled substance (CII) because it contains lisdexamfetamine dimesylate that can be a target for people who abuse prescription medicines or street drugs. Keep lisdexamfetamine dimesylate chewable tablets in a safe place to protect it from theft. Never give your lisdexamfetamine dimesylate chewable tablets to anyone else because it may cause death or harm them. Selling or giving away lisdexamfetamine dimesylate chewable tablets may harm others and is against the law.

    Do not take lisdexamfetamine dimesylate chewable tablets if you or your child are: 
    • allergic to amphetamine products or any of the ingredients in lisdexamfetamine dimesylate chewable tablets. See the end of this Medication Guide for a complete list of ingredients in lisdexamfetamine dimesylate chewable tablets.
    • taking, or have stopped taking in the last 14 days, a medicine called a Monoamine Oxidase Inhibitor (MAOI).
    • being treated with the antibiotic linezolid or intravenous methylene blue.
    Before taking lisdexamfetamine dimesylate chewable tablets, tell your healthcare provider about all medical conditions, including if you or your child: 
    • have heart problems, heart disease, heart defects, or high blood pressure 
    • have mental problems including psychosis, mania, bipolar illness, or depression or have a family history of suicide, bipolar illness, or depression 
    • have circulation problems in fingers and toes 
    • have kidney problems
    • have or had repeated movements or sounds (tics) or Tourette’s syndrome, or have a family history of tics or Tourette’s syndrome 
    • are pregnant or plan to become pregnant. Lisdexamfetamine dimesylate chewable tablets may harm the unborn baby. 
    • There is a pregnancy registry for females who are exposed to lisdexamfetamine dimesylate chewable tablets during pregnancy. The purpose of the registry is to collect information about the health of females exposed to lisdexamfetamine dimesylate chewable tablets and their baby. If you or your child becomes pregnant during treatment with lisdexamfetamine dimesylate chewable tablets, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visit online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/adhd-medications/. 
    • are breastfeeding or plan to breastfeed. Lisdexamfetamine dimesylate passes into breast milk. You should not breastfeed during treatment with lisdexamfetamine dimesylate chewable tablets. Talk to your healthcare provider about the best way to feed the baby during treatment with lisdexamfetamine dimesylate chewable tablets.
    Tell your healthcare provider about all the medicines that you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
    Lisdexamfetamine dimesylate chewable tablets can affect the way other medicines work and other medicines may affect how lisdexamfetamine dimesylate chewable tablets works. Taking lisdexamfetamine dimesylate chewable tablets with other medicines can cause serious side effects. Sometimes the doses of other medicines will need to be changed while taking lisdexamfetamine dimesylate chewable tablets.

    Especially tell your healthcare provider if you or your child take: 
    • selective serotonin reuptake inhibitors (SSRIs) 
    • serotonin norepinephrine reuptake inhibitors (SNRIs) 
    • medicines used to treat migraine headaches called triptans 
    • tricyclic antidepressants 
    • lithium
    • fentanyl 
    • tramadol 
    • tryptophan
    • buspirone
    • St. John’s Wort

    Keep a list of all medicines to show your healthcare provider and pharmacist when you get a new medicine. Your healthcare provider will decide if lisdexamfetamine dimesylate chewable tablets can be taken with other medicines.
    Do not start any new medicine during treatment with lisdexamfetamine dimesylate chewable tablets without talking to your healthcare provider first.


    How should lisdexamfetamine dimesylate chewable tablets be taken? 
    • Take lisdexamfetamine dimesylate chewable tablets exactly as prescribed by your healthcare provider. 

    • Your healthcare provider may change the dose if needed.

    • Take lisdexamfetamine dimesylate chewable tablets 1 time each day in the morning with or without food. 

    • Lisdexamfetamine dimesylate comes inchewable tablets.


    Taking lisdexamfetamine dimesylate chewable tablets: 
    • Chew lisdexamfetamine dimesylate chewable tablets completely before swallowing.


    If you or your child take too much lisdexamfetamine dimesylate, call your healthcare provider or Poison Helplineat 1-800-222-1222 or go to the nearest hospital emergency room right away.

    What are the possible side effects of lisdexamfetamine dimesylate chewable tablets?
    Lisdexamfetamine dimesylate chewable tablets may cause serious side effects, including:
    • See “What is the most important information I should know about lisdexamfetamine dimesylate chewable tablets?” 
    • Slowing of growth (height and weight) in children. Children should have their height and weight checked often during treatment with lisdexamfetamine dimesylate chewable tablets. Lisdexamfetamine dimesylate chewable tablets treatment may be stopped if your child is not growing or gaining weight.             
    • Circulation problems in fingers and toes (Peripheral vasculopathy, including Raynaud’s phenomenon).
      Signs and symptoms may include: 

    • Fingers or toes may feel numb, cool, painful 
    • Fingers or toes may change color from pale, to blue, to red
      Tell your healthcare provider if you or your child have numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes.
      Call your healthcare provider right away if you or your child have any signs of unexplained wounds appearing on fingers or toes during treatment with lisdexamfetamine dimesylate chewable tablets. 
    • New or worsening tics or worsening Tourette’s syndrome. Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette’s syndrome during treatment with lisdexamfetamine dimesylate chewable tablets.
    • Serotonin Syndrome. A potentially life-threatening problem called serotonin syndrome may happen when lisdexamfetamine dimesylate chewable tablets are taken with certain other medicines. Stop taking lisdexamfetamine dimesylate chewable tablets and call your healthcare provider or go to the nearest hospital emergency room right away if you or your child develop any of the following signs and symptoms of serotonin syndrome:
    • agitation            
    • fast heartbeat
    • flushing
    • seizures 
    • coma 
    • sweating
    • loss of coordination     
    • confusion
    • dizziness 
    • tremors, stiff muscles, or muscle twitching 
    • seeing or hearing things that are not real (hallucination) 
    • changes in blood pressure 
    • high body temperature (hyperthermia) 
    • nausea, vomiting, diarrhea
    The most common side effects of lisdexamfetamine dimesylate chewable tablets in children 6 to 17 years old and adults with ADHD include:
    • loss of appetite (anorexia) 
    • anxiety             
    • decreased appetite 

    • weight loss 

    • diarrhea 

    • dizziness 

    • dry mouth 

    • irritability

    • trouble sleeping 

    • nausea 

    • stomach pain 

    • vomiting  
    The most common side effects of lisdexamfetamine dimesylate chewable tablets in adults with BED include:
    • dry mouth 

    • trouble sleeping 

    • decreased appetite

    • increased heart rate 

    • constipation 

    • feeling jittery

    • anxiety
    These are not all the possible side effects of lisdexamfetamine dimesylate chewable tablets.
    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
    How should I store lisdexamfetamine dimesylate chewable tablets?
    • Store lisdexamfetamine dimesylate chewable tablets in a safe place (like a locked cabinet) and in a tightly closed container at room temperature between 68°F to 77°F (20°C to 25°C). 
    • Protect lisdexamfetamine dimesylate chewable tablets from light. 
    • Dispose of remaining, unused, or expired lisdexamfetamine dimesylate chewable tablets by a medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is available, mix lisdexamfetamine dimesylate chewable tablets with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw away lisdexamfetamine dimesylate chewable tablets in the household trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.
    Keep lisdexamfetamine dimesylate chewable tablets and all medicines out of the reach of children.

    General information about the safe and effective use of lisdexamfetamine dimesylate chewable tablets.
    Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use lisdexamfetamine dimesylate chewable tablets for a condition for which it was not prescribed. Do not give lisdexamfetamine dimesylate chewable tablets to other people, even if they have the same symptoms that you have. It may harm them and it is against the law. You can ask your pharmacist or healthcare provider for information about lisdexamfetamine dimesylate chewable tablets that is written for healthcare professionals.

    What are the ingredients in lisdexamfetamine dimesylate chewable tablets?
    Active ingredient: lisdexamfetamine dimesylate
    Chewable Tablet Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose and gaur gum, sucralose, N-C strawberry flavorart. 
    For more information, go to www.novadozpharma.com or call 1-855-668-2369
    Manufactured by:
    MSN Pharmaceuticals Inc
    Piscataway, NJ 08854
    Distributed by:
    Novadoz Pharmaceuticals LLC
    Piscataway, NJ 08854-3714.

     This Medication Guide has been approved by the U.S. Food and Drug Administration.                                                                     Issued: 11/2023
                                                                                                                         

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Lisdexamfetamine dimesylate chewable tablets-10 mg-100's-container-label

    lisdex-dimesy-chew-tabs-10mg-100s-cntr-label 

    Lisdexamfetamine dimesylate chewable tablets-20 mg-100's-container-label 

    lisdex-dimesy-chew-tabs-20mg-100s-cntr-label

    Lisdexamfetamine dimesylate chewable tablets-30 mg-100's-container-label 

    lisdex-dimesy-chew-tabs-30mg-100s-cntr-label

    Lisdexamfetamine dimesylate chewable tablets-40 mg-100's-container-label 

    lisdex-dimesy-chew-tabs-40mg-100s-cntr-label

    Lisdexamfetamine dimesylate chewable tablets-50 mg-100's-container-label

    lisdex-dimesy-chew-tabs-50mg-100s-cntr-label 

    Lisdexamfetamine dimesylate chewable tablets-60 mg-100's-container-label

    lisdex-dimesy-chew-tabs-60mg-100s-cntr-label

  • INGREDIENTS AND APPEARANCE
    LISDEXAMFETAMINE DIMESYLATE 
    lisdexamfetamine dimesylate tablet, chewable
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 72205-132
    Route of AdministrationORALDEA ScheduleCII    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    LISDEXAMFETAMINE DIMESYLATE (UNII: SJT761GEGS) (LISDEXAMFETAMINE - UNII:H645GUL8KJ) LISDEXAMFETAMINE DIMESYLATE10 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MANNITOL (UNII: 3OWL53L36A)  
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    GUAR GUM (UNII: E89I1637KE)  
    SUCRALOSE (UNII: 96K6UQ3ZD4)  
    Product Characteristics
    ColorWHITE (White or off-white) Scoreno score
    ShapeROUNDSize7mm
    FlavorSTRAWBERRYImprint Code m169
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 72205-132-91100 in 1 BOTTLE; Type 0: Not a Combination Product02/17/2024
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21830602/02/2024
    LISDEXAMFETAMINE DIMESYLATE 
    lisdexamfetamine dimesylate tablet, chewable
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 72205-133
    Route of AdministrationORALDEA ScheduleCII    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    LISDEXAMFETAMINE DIMESYLATE (UNII: SJT761GEGS) (LISDEXAMFETAMINE - UNII:H645GUL8KJ) LISDEXAMFETAMINE DIMESYLATE20 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MANNITOL (UNII: 3OWL53L36A)  
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    GUAR GUM (UNII: E89I1637KE)  
    SUCRALOSE (UNII: 96K6UQ3ZD4)  
    Product Characteristics
    ColorWHITE (White or off-white) Scoreno score
    ShapeHEXAGON (6 sided)Size9mm
    FlavorSTRAWBERRYImprint Code m170
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 72205-133-91100 in 1 BOTTLE; Type 0: Not a Combination Product02/17/2024
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21830602/02/2024
    LISDEXAMFETAMINE DIMESYLATE 
    lisdexamfetamine dimesylate tablet, chewable
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 72205-134
    Route of AdministrationORALDEA ScheduleCII    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    LISDEXAMFETAMINE DIMESYLATE (UNII: SJT761GEGS) (LISDEXAMFETAMINE - UNII:H645GUL8KJ) LISDEXAMFETAMINE DIMESYLATE30 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MANNITOL (UNII: 3OWL53L36A)  
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    GUAR GUM (UNII: E89I1637KE)  
    SUCRALOSE (UNII: 96K6UQ3ZD4)  
    Product Characteristics
    ColorWHITE (White or off-white) Scoreno score
    ShapeTRIANGLESize11mm
    FlavorSTRAWBERRYImprint Code m171
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 72205-134-91100 in 1 BOTTLE; Type 0: Not a Combination Product02/17/2024
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21830602/02/2024
    LISDEXAMFETAMINE DIMESYLATE 
    lisdexamfetamine dimesylate tablet, chewable
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 72205-135
    Route of AdministrationORALDEA ScheduleCII    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    LISDEXAMFETAMINE DIMESYLATE (UNII: SJT761GEGS) (LISDEXAMFETAMINE - UNII:H645GUL8KJ) LISDEXAMFETAMINE DIMESYLATE40 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MANNITOL (UNII: 3OWL53L36A)  
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    GUAR GUM (UNII: E89I1637KE)  
    SUCRALOSE (UNII: 96K6UQ3ZD4)  
    Product Characteristics
    ColorWHITE (White or off-white) Scoreno score
    ShapeCAPSULESize14mm
    FlavorSTRAWBERRYImprint Code m172
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 72205-135-91100 in 1 BOTTLE; Type 0: Not a Combination Product02/17/2024
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21830602/02/2024
    LISDEXAMFETAMINE DIMESYLATE 
    lisdexamfetamine dimesylate tablet, chewable
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 72205-136
    Route of AdministrationORALDEA ScheduleCII    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    LISDEXAMFETAMINE DIMESYLATE (UNII: SJT761GEGS) (LISDEXAMFETAMINE - UNII:H645GUL8KJ) LISDEXAMFETAMINE DIMESYLATE50 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MANNITOL (UNII: 3OWL53L36A)  
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    GUAR GUM (UNII: E89I1637KE)  
    SUCRALOSE (UNII: 96K6UQ3ZD4)  
    Product Characteristics
    ColorWHITE (White or off-white) Scoreno score
    ShapeSQUARESize10mm
    FlavorSTRAWBERRYImprint Code m173
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 72205-136-91100 in 1 BOTTLE; Type 0: Not a Combination Product02/17/2024
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21830602/02/2024
    LISDEXAMFETAMINE DIMESYLATE 
    lisdexamfetamine dimesylate tablet, chewable
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 72205-137
    Route of AdministrationORALDEA ScheduleCII    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    LISDEXAMFETAMINE DIMESYLATE (UNII: SJT761GEGS) (LISDEXAMFETAMINE - UNII:H645GUL8KJ) LISDEXAMFETAMINE DIMESYLATE60 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MANNITOL (UNII: 3OWL53L36A)  
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    GUAR GUM (UNII: E89I1637KE)  
    SUCRALOSE (UNII: 96K6UQ3ZD4)  
    Product Characteristics
    ColorWHITE (White or off-white) Scoreno score
    ShapeDIAMONDSize14mm
    FlavorSTRAWBERRYImprint Code m174
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 72205-137-91100 in 1 BOTTLE; Type 0: Not a Combination Product02/17/2024
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21830602/02/2024
    Labeler - Novadoz Pharmaceuticals LLC (081109687)
    Establishment
    NameAddressID/FEIBusiness Operations
    MSN Pharmaceuticals Inc.079229051ANALYSIS(72205-132, 72205-133, 72205-134, 72205-135, 72205-136, 72205-137) , MANUFACTURE(72205-132, 72205-133, 72205-134, 72205-135, 72205-136, 72205-137)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.